Successful use of liposome encapsulated amphotericin to treat invasive aspergillosis following failure of conventional amphotericin.
We describe a case of proven invasive pulmonary aspergillosis in a neutropenic patient in whom disease progression occurred during treatment with conventional amphotericin B despite neutrophil recovery. Treatment with liposomal encapsulated amphotericin B resulted in clinical and radiological improvement and the clearance of aspergillus spores from the sputum.
Richards
E M
EM
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Apperley
J F
JF
Marcus
R E
RE
D000666:Amphotericin B / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D001231:Aspergillus flavus; D001232:Aspergillus fumigatus; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B